ATAI Nov 2024 0.500 call
| Previous Close | 1.3000 |
| Open | 1.3000 |
| Bid | 0.7000 |
| Ask | 1.5000 |
| Strike | 0.50 |
| Expire Date | 2024-11-15 |
| Day's Range | 1.3000 - 1.3000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 5 |
GlobeNewswireatai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024. Details of the company’s participation: Format: Fireside ChatDate and Time: Thursday June 6 at 10:00 A.M. ETLocation: New YorkWebcast link
- GlobeNewswire
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer (“CEO”) and Chairman of Marinus Pharma
- GlobeNewswire
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24Beckley Psytech’s Phase 2a study of BPL-003 in TRD patients showed rapid and durable antidepressant effects; Phase 2b topline data expected in 2H’24Compass Pathways’ Phase 2 study of COMP360 in PTSD patients demonstrated durable improvement in symptoms; Phase 3 data of COMP360 in TRD patients expected in 4Q’24 Co-Founder Florian Brand to step down as
